Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a ran
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Until now, ... (relational tables) or unstructured data (document stores). SQL products ... products have basically managed the wide assortment of unstructured ... to work with Big Data is with a NoSQL ... the various aspects of all Big Data issues. ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 When David ... and long-time friend of Mark Brnovich, was asked to ... Republican nomination for the Attorney General seat in the ... quickly gathered the support of Cardinal Hall of Fame ... Cardinals Derek Kennard and Mark Walczak. Green, Kennard and ...
(Date:8/28/2014)... banker arrives at the emergency department with complaints ... alcohol every dayoften at business lunches, and at ... decided to quit drinking and had his last ... It,s a common scenario in emergency rooms across ... and develops withdrawal. , Withdrawal is a potentially ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... Inhibiting a protein involved in bone metabolism can delay the ... with a particular form of prostate cancer, a researcher will ... Professor Stphane Oudard, Head of ... says that his team,s research on the effects of the ...
... for prostate cancer will be unveiled at the 2011 ... Led by Dr David rsted at the Copenhagen University ... with benign prostate enlargement have an increased risk of ... shows that monitoring prostate-specific antigen levels can be used ...
... News) -- People,s bodies build up vitamin D through exposure ... live in areas of the United States with low sunlight ... who live in the same places. The researchers say ... change. "This study shows that across-the-board vitamin D recommendations just ...
... -- Although some studies have suggested that men can ... their voices, a new study appears to dispel that notion ... women are ovulating by examining changes in their voices over ... Unlike previous studies, the researchers behind the new study ...
... Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting ... killers. "It is a memorable day in the history ... table gives a strong sense of the burden it represents ... challenge for all nations in the world2", declared Professor Michel ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
Cached Medicine News:Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 2Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 3Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 4Health News:2 new cost-effective ways to predict prostate cancer 2Health News:2 new cost-effective ways to predict prostate cancer 3Health News:2 new cost-effective ways to predict prostate cancer 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:Depression After Cancer Keeps Some From Follow-Up Care 2
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: